NDAORALTABLET, FOR SUSPENSIONPriority Review
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
15
Mechanism of Action
Hemoglobin S Polymerization Inhibitors
Pharmacologic Class:
Hemoglobin S Polymerization Inhibitor
Clinical Trials (5)
Assessing Physical Function in Sickle Cell Patients Taking Voxelotor
Started Oct 2023
6 enrolled
Sickle Cell Disease
Voxelotor Brain Oxygenation and Neurocognitive Study
Started Aug 2023
0Sickle Cell Disease
Voxelotor CYP and Transporter Cocktail Interaction Study
Started Apr 2023
44 enrolled
Sickle Cell Disease
Hemolysis Related Complications in SCD. A Phase II Study With Voxelotor
Started Mar 2023
30 enrolled
Sickle Cell Disease
Voxelotor Neurocognitive Function Study
Started Jun 2022
1 enrolled
Sickle Cell Disease
Loss of Exclusivity
LOE Date
Dec 2, 2036
130 months away
Patent Expiry
Dec 2, 2036
Exclusivity Expiry
Dec 17, 2028